Clinical trials: Hemolysis
Sickle Cell Disease
Transcranial Photobiomodulation Treatment in Patients With Sickle Cell Disease
Participants are being asked to take part in this clinical trial, a type of research study, because investigators want to learn more about oxygen usage in the brain.
- Trial name
- PHOTOSCAN (NCT06797583)
- Testing
- Active Transcranial Photobiomodulation (TPBM)
- Volunteers
- 60 people
- Sponsor
- St. Jude Children's Research Hospital
Beta Thalassemia Intermedia
Study of SDMB (2,2 Dimethylbutyrate, Sodium Salt) in Beta Thalassemia Intermedia in Thailand
Beta thalassemia intermedia is an inherited blood disease caused by molecular mutations which reduce the beta globin protein chain of adult hemoglobin A, the protein in red blood cells which carries oxygen throughout the body.
- Trial name
- ST20-P2T (NCT01609595)
- Testing
- sodium 2,2 dimethylbutyrate
- Where
- Thailand
- Volunteers
- 10 people
- Sponsor
- Boston University
Sickle Cell Disease
Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
The proposed research is designed to test the global hypothesis that inhaled corticosteroids (ICS), a therapy developed to treat asthma, will prevent vasoocclusive painful episodes in adults with Sickle Cell Disease (SCD) who…
- Trial name
- IMPROVE (NCT02061202)
- Testing
- Mometasone Furoate
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Jeffrey Glassberg
Sickle Cell Disease, Umbilical Cord Blood
US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease
The application of experimental hematopoietic cell transplantation (HCT) therapy in sickle-cell disease (SCD) must strike a balance between the underlying disease severity and the possibility of a direct benefit of the treatment…
- Conditions
- Sickle Cell Disease, Umbilical Cord Blood, Hematopoietic Cell Proliferation
- Trial name
- NCT04594031
- Testing
- ECT-001-CB (UM171-Expanded Cord Blood Transplant)
- Where
- 2 sites in United States
- Sponsor
- ExCellThera inc.
Drepanocytosis
Study of a Deformability Parameter of Red Blood Cell
Sickle-cell disease is one of the most common severe monogenic disorders in the world, it results in the synthesis of abnormal hemoglobin (HbS) instead of hemoglobin A.
- Trial name
- FITRED (NCT05850156)
- Testing
- basal blood collection, blood collection M6, blood collection M12
- Volunteers
- 130 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Paroxysmal Nocturnal Hemoglobinuria
Danicopan PMS in Korea
As part of a post-approval commitment, the Korean health authority requests a study to characterize safety and effectiveness in patients who are treated with Danicopan as an add-on to ravulizumab or eculizumab in normal clinical…
- Trial name
- NCT07457151
- Where
- 4 sites in South Korea
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis
Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases
Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues, leading to chronic inflammation and damage to organs such as the kidneys, lungs, muscles, nerves, or blood cells.
- Conditions
- Relapsed/Refractory Systemic Lupus Erythematosus, Relapsed/Refractory Systemic Sclerosis, Relapsed/Refractory Idiopathic Inflammatory Myopathies, Relapsed/Refractory sjögren's Syndrome
- Trial name
- NCT07361094
- Testing
- Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy
- Where
- China
- Sponsor
- Beijing Boren Hospital
Sickle Cell Disease, Acute Chest Syndrome
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients…
- Trial name
- TOCIACS (NCT06818266)
- Testing
- Tocilizumab (RoActemra®, 20 mg/mL).
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anemia, Sickle Cell
A Safety, Efficacy, and Pharmacokinetic (PK) Study of HBI-002, an Oral Carbon Monoxide (CO) Therapeutic, in Subjects With Sickle Cell Disease (SCD)
This is a multi-center, open label Phase 2a clinical trial in subjects with sickle cell disease to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of HBI-002, an orally administered liquid containing carbon…
- Trial name
- NCT06144749
- Testing
- HBI-002
- Where
- 2 sites in Panama
- Volunteers
- 13 people
- Sponsor
- Hillhurst Biopharmaceuticals, Inc.
Anemia, Sickle Cell
MAST - Magnesium for Sickle Cell Acute Crisis in Children
The purpose of this study is to determine if intravenous magnesium sulfate treatment is effective in reducing the length of stay and pain in children with sickle cell disease suffering an acute vaso-occlusive episode.
- Trial name
- NCT00313963
- Testing
- Magnesium Sulfate, Normal Saline
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- The Hospital for Sick Children
Chronic Hemolysis, VKA
Possibility to Stop Perdialytic Heparin Therapy in Hemodialysed Patients With HeprAN ™ Membrane and Treated by Long-term Anticoagulation With VKA
Use HeprAN ™ membrane (coated with heparin) should be allow the success of dialysis sessions, with adequate dialysis parameters, in patients treated by long-term anticoagulation with VKA, without addition of heparin perdialytic.
- Conditions
- Chronic Hemolysis, VKA, Anticoagulants / Administration & Dosage, Coated Materials
- Trial name
- REMARK (NCT04462614)
- Testing
- Decrease per-dialytic heparin therapy
- Where
- France
- Volunteers
- 49 people
- Sponsor
- CHU de Reims
Sickle Cell Disease
Iron Mediated Vascular Disease in Sickle Cell Anemia Patients
The purpose of this research study is to determine the frequency and severity of iron overload in patients with Sickle Cell Anemia and its relationship to blood vessel function.
- Trial name
- NCT01239901
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Los Angeles
Paroxysmal Nocturnal Hemoglobinuria, PNH
To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.
Phase I Study Evaluating Safety, Tolerability, PK and PD of Single and Multiple Doses of TUL321 Capsule in Healthy Participants and Food Effect on PK
- Trial name
- NCT07760467
- Testing
- Part1: TUL321, Part2: TUL321
- Where
- China
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Zhuhai United Laboratories Co., Ltd.
Sickle Cell Disease
Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease
This research study is designed to investigate a new potential medicine for mobilizing stem cells and apheresis collection in patients with Sickle Cell Disease. MGTA-145, the new potential medicine, will be given with plerixafor.
- Trial name
- NCT05445128
- Testing
- MGTA-145, Plerixafor
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Ensoma
Sickle Cell Disease
Omega-3 Fatty Acids in Sickle Cell Disease
The purpose of this study is to determine the safety of a new formulation of the omega-3 fatty acids Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) and to assess whether it decreases inflammation and inflammatory pain…
- Trial name
- NCT02947100
- Testing
- SCD-Omegatex™
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Robin E. Miller
Sickle Cell Disease
HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen
Sickle cell disease (SCD) is the most common inherited blood disorder in Saudi Arabia . Its clinical severity is widely heterogeneous among patients who share the same genetic mutation .
- Trial name
- NCT02776202
- Testing
- Fludarabine monophosphate
- Where
- Saudi Arabia
- Volunteers
- 15 people
- Sponsor
- National Guard Health Affairs
Paroxysmal Nocturnal Hemoglobinuria
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH
Evaluation of the Efficacy and Safety of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria .
- Trial name
- NCT04085601
- Testing
- APL-2
- Where
- 30 sites in Colombia, Hong Kong and 8 more
- Volunteers
- 53 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Thalassemia
The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation
Hypercoagulable state is well recognized in patients with β-thalassemia. Evidences of hypercoagulability include abnormal expression of phosphatidylserine on red blood cell (rbc) surface and consequent increased platelet…
- Trial name
- NCT00789516
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Thalassemia
A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia
This is a Phase 2, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) versus placebo in adults with non-transfusion dependent beta (β)-thalassemia.
- Trial name
- BEYOND (NCT03342404)
- Testing
- Luspatercept, Best Supportive Care (BSC)
- Where
- 16 sites in United States, Greece and 4 more
- Volunteers
- 145 people
- Sponsor
- Celgene
Paroxysmal Nocturnal Hemoglobinuria
A Study to Evaluate the Efficacy and Safety of Oral HRS-5965 in Adult Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
A study of the efficacy and safety of HRS-5965 capsules compared to eculizumab for 24 weeks in patients with PNH.
- Trial name
- NCT06593938
- Testing
- HRS-5965 capsule, Eculizumab Injection
- Where
- 2 sites in China
- Volunteers
- 76 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.